Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AK117 + chemotherapy
- Development stage
- Unknown
- Lead developer
- Akeso
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
AK117 + chemotherapy refers to the combination therapy of **AK117 (ligufalimab)**, a humanized IgG4 monoclonal antibody targeting CD47, with one or more chemotherapy agents. AK117 binds to CD47 and blocks its interaction with SIRPα, thereby disrupting the "don't eat me" signal that cancer cells use to evade macrophage-mediated phagocytosis. This blockade enhances the immune-mediated clearance of tumor cells. Combining AK117 with chemotherapy agents, such as azacitidine or XELOX (oxaliplatin + capecitabine), has shown encouraging safety and efficacy in patients with various cancers, including advanced gastric/gastroesophageal junction (G/GEJ) adenocarcinoma and higher-risk myelodysplastic syndrome (MDS). The combination is under evaluation in several phase II clinical trials, and early results indicate enhanced anti-tumor activity and a tolerable safety profile, with common adverse events including anemia and gastrointestinal symptoms[2][3][6].
- Other names
- ligufalimab + chemotherapy
02
Targets
CD47 (Cluster of Differentiation 47)TS (Thymidylate synthase)DNA
Beyond the preview
Go deeper on AK117 + chemotherapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AK117 + chemotherapy.